Canaccord Genuity Maintains Buy on Verona Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Verona Pharma (NASDAQ:VRNA) with a $35 price target.
June 27, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Verona Pharma with a $35 price target.
The reaffirmation of a Buy rating and a $35 price target by a reputable analyst is likely to positively impact Verona Pharma's stock price in the short term as it reinforces investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100